Interleukin-1 beta-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study


Gül A. , Tugal-Tutkun I. , Dınarello C. A. , Reznıkov L., Esen B. A. , Mırza A., ...More

ANNALS OF THE RHEUMATIC DISEASES, vol.71, pp.563-566, 2012 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 71
  • Publication Date: 2012
  • Doi Number: 10.1136/annrheumdis-2011-155143
  • Title of Journal : ANNALS OF THE RHEUMATIC DISEASES
  • Page Numbers: pp.563-566

Abstract

Objective Uveitis and retinal vasculitis are sight-threatening manifestations of Behcet's disease with limited treatment options. This pilot study aimed to evaluate the safety, pharmacokinetics and clinical activity of XOMA 052 (gevokizumab), a recombinant humanised anti-interleukin 1 beta antibody, in Behcet's disease patients with uveitis.